Incrementalism in Pharmaceutical Research: Incentives and Policy Implications
نویسنده
چکیده
The tremendous commercial success of drugs which scientific data suggest are of no benefit to most patients relative to pre-existing drugs is illustrative of a phenomenon in pharmaceutical markets whereby products can become commercially successful even though their social costs vastly outweigh their social benefits. This suggests that a confluence of market failures, patent laws and FDA regulation of pharmaceuticals is creating perverse incentives that both encourage inefficient allocation of resources and decrease consumer access. In this paper, I explore this phenomenon by addressing two related questions. First, how can incremental improvements in medications be characterized so as to identify which incremental research should be encouraged or discouraged by patent and regulatory law? And second, which doctrinal or policy levers should Congress and the courts use to reduce incentives for undesirable incrementalism? Part I of this paper describes the economic and legal context that must inform pharmaceutical policy. Part II attempts to characterize pharmaceutical innovations in terms of their social value and degree of innovation, and thereby to identify the types of innovations that patent law and FDA regulations should promote. Part III presents possible policy solutions for tailoring incentives to discourage undesirable forms of incrementalism and encourage valuable forms of innovation. In particular, mandatory and voluntary comparative testing of drugs, increasing the standard of nonobviousness for patentability, improvements to the patent application process, and penalties for holders of invalid patents in paragraph IV challenges are explored as means to enhance the correlation between the social benefits and royalties derived from pharmaceutical patents.
منابع مشابه
A Model of Choice for Public Policy
Punctuated equilibrium is supposed to be a viable alternative to incrementalism, and, indeed, the authors of the model have sometimes made such claims. But punctuated equilibrium was developed to explain change in policy subsystems and does not serve as a complete model of policy choice in the same way that incrementalism has served. This article develops a full-blown and viable model of choice...
متن کاملPunctuated Equilibrium Models in Organizational Decision Making
8.1 Two Research Conundrums..................................................................................................134 8.1.1 Lindblom’s Theory of Administrative Incrementalism...........................................134 8.1.2 Wildavsky’s Theory of Budgetary Incrementalism.................................................135 8.1.3 The Diverse Meanings of Budgetary “Incrementalism”.......
متن کاملIncrementalism, Intelligent Trial-and-error, and the Future of Political Decision Theory
Although incrementalism has enjoyed widespread acceptance within political science, it has not spawned a lively research tradition leading to cumulative refinement and amplification of the core concepts. Nor has it provided much guidance for policy making, in part because scholars never attempted to clarify how decision makers could become better incrementalists. This is due in part, we suggest...
متن کاملTake the Money and Run: The Challenges of Designing and Evaluating Financial Incentives in Healthcare; Comment on “Paying for Performance in Healthcare Organisations”
Many countries are turning their attention to the use of explicit financial incentives to drive desired improvements in healthcare performance. However, we have only a weak evidence-base to inform policy in this area. The research challenge is to generate robust evidence on what financial incentives work, under what circumstances, for whom and with what intended and unintended consequences.
متن کامل